Silverfin false false 31/05/2025 31/05/2025 01/06/2024 The principal activity of the Company during the financial year was specialists medical practice activities. Amanda Braybrooke 27/05/2020 Dr Jeremy Braybrooke 27/05/2020 12624341 2025-05-31 12624341 bus:Director1 2025-05-31 12624341 bus:Director2 2025-05-31 12624341 2024-05-31 12624341 core:CurrentFinancialInstruments 2025-05-31 12624341 core:CurrentFinancialInstruments 2024-05-31 12624341 2024-06-01 2025-05-31 12624341 bus:Micro-entities 2024-06-01 2025-05-31 12624341 bus:FilletedAccounts 2024-06-01 2025-05-31 12624341 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 12624341 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 12624341 bus:Director1 2024-06-01 2025-05-31 12624341 bus:Director2 2024-06-01 2025-05-31 12624341 2023-06-01 2024-05-31 iso4217:GBP xbrli:pure

Company No: 12624341 (England and Wales)

# BRISTOL ONCOLOGY LIMITED

### Unaudited Financial Statements
For the financial year ended 31 May 2025
Pages for filing with the registrar

BRISTOL ONCOLOGY LIMITED

## UNAUDITED FINANCIAL STATEMENTS

For the financial year ended 31 May 2025

Contents

BRISTOL ONCOLOGY LIMITED

## BALANCE SHEET

As at 31 May 2025
BRISTOL ONCOLOGY LIMITED

## BALANCE SHEET (continued)

For the financial year ended 31 May 2025

|  | 31.05.2025 |  | 31.05.2024
|  | £ |  | £
Fixed assets |  | 44,900 |  | 56,531
Current assets |  | 325,966 |  | 181,752
Creditors: amounts falling due within one year |  | ( 52,125) |  | ( 15,882)
Net current assets |  | 273,841 |  | 165,870
Total assets less current liabilities |  | 318,741 |  | 222,401
Accruals and deferred income |  | ( 1,512) |  | ( 1,453)
Net assets |  | 317,229 |  | 220,948
Capital and reserves |  | 317,229 |  | 220,948

For the financial year ending 31 May 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
- These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
- These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Bristol Oncology Limited (registered number: 12624341) were approved and authorised for issue by the Board of Directors on 20 February 2026 and were signed on its behalf by:

Dr Jeremy Braybrooke Director |

BRISTOL ONCOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 May 2025
BRISTOL ONCOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the For the financial year ended 31 May 2025

#### 1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 12624341). The address of its registered office is 5th Floor 25 King Street, Bristol, BS1 4PB, United Kingdom.

#### 2. Employees

| 31.05.2025 |  | 31.05.2024
| Number |  | Number
Monthly average number of persons employed by the Company during the financial year, including directors | 2 |  | 2